Clinical Trials

Are you an adult who is healthy or has problems with the level of cholesterol or other lipids in the blood? This study is gathering information on the risk factors for very high or very low levels of lipids, or fats, in the blood. Researchers will collect participants’ demographic information, medical history, and blood samples. To participate in this study, you must be at least 18 years old. This study takes place in Dallas, Texas.

Have you or your child been diagnosed with cystic fibrosis, and are you interested a trial medicine already in use for some people living with the condition? A medicine called Trikafta is used to treat cystic fibrosis that is caused by a specific gene mutation. This study is testing whether Trikafta can also be used to treat cystic fibrosis that is caused by other gene mutations. Participants in this study must be at least 12 years old. This study takes place in Birmingham, Alabama; Atlanta, Georgia; and Houston, Texas.

Are you between 14 and 22 weeks pregnant, and think that you might have obstructive sleep apnea (OSA) ? This study is testing whether using CPAP to treat obstructive sleep apnea in pregnant women can help lower the risk of hypertensive disorders during pregnancy. To participate in this study, you must be at least 18 years old. This study takes place in multiple locations in the United States.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

This study will leverage state-of-the-art, 24-hour behavior assessment in each trimester of pregnancy and examine associations with adverse pregnancy outcomes to inform guidelines and future interventions designed to improve women's pregnancy and long-term cardiovascular health.

The overall goal of this study is to use state-of-the-art monitors to objectively measure the 24-hour behavioral cycle in each trimester of pregnancy, and to examine associations of these behaviors with hypertensive disorders of pregnancy and other adverse pregnancy outcomes linked with future cardiovascular disease risk.